NEWTON-CABG: Evolocumab Did Not Improve Vein Graft Patency After CABG
Key Points: Saphenous vein graft (SVG) failure is common after coronary artery bypass grafting (CABG), with an occlusion rates of 20% within the first year after... Read more.
Essence-TIMI 73b: Olezarsen Safely and Effectively Reduces Triglycerides in Patients With Moderate Hypertriglyceridemia and High CV Risk
Key Points: Olezarsen, an anti-sense oligonucleotide targeting APOC3 mRNA, is approved to lower triglycerides (TG) in adults with rare familial chylomicronemia,... Read more.
VICTOR: Vericiguat Did Not Meet Primary Endpoint But Reduced CV Death in Stable, Ambulatory HFrEF
Key Points: The VICOTRIA trial previously demonstrated that vericiguat reduced the risk of heart failure (HF) hospitalization or cardiovascular (CV) death in patients... Read more.
VICTOR + VICTORIA: Vericiguat Showed Benefits Across the Spectrum of HFrEF Severity
Key Points: VICTORIA and VICTOR and were randomized trials that evaluated vericiguat versus placebo in HFrEF patients with and without recent decompensation, respectively.... Read more.
SUMMIT: Tirzepatide Improved Renal Function in Patients with HFpEF, Obesity, and CKD
Key Points The SUMMIT randomized control trial demonstrated that tirzepatide significantly reduced worsening heart failure events among patients with HFpEF and obesity... Read more.
EKSTROM Trial: Low-dose Colchicine Reduced Total Plaque Volume on CCTA, but Not Low Attenuation Plaque
Key Points The COLCOT trial demonstrated colchicine improved coronary plaque characteristics in patients with acute coronary syndrome compared with placebo. EKSTROM... Read more.
GCVRC: Controlling Hypertension and Stopping Smoking at Midlife Associated With Greatest Gains in Additional Life-years Free of CVD
Key Points Five classic risk factors – HTN, DM, HLD, underweight/obesity, and smoking – account for 50% of the global burden of CV disease. The purpose of... Read more.
ALLEPRE: Fully Nursing-Led Heart Health Counseling Program Reduces CV Outcomes After ACS
Key Points Nurses are increasingly responsible for cardiovascular risk management, but randomized data supporting this approach is lacking, especially for secondary... Read more.
HOST-BR: 3 Months Of DAPT Might be Reasonable For Both Low- And High-Bleeding Risk Patients After PCI With DES
Key Points After DES placement, guidelines recommend considering shorter DAPT duration (e.g. 1-3 months) for those with high bleeding risk (HBR) and longer DAPT... Read more.
SOUL: Oral Semaglutide Reduced CV Events In High-Risk Patients With T2DM with ASCVD or CKD
Key Points Injectable semaglutide, a GLP-1 receptor agonist, reduces CV events in patients with T2DM, however whether the oral form of semaglutide confers the same... Read more.